Myogenic differentiation of mesenchymal stem cells in a newly developed neurotised AV-loop model
Standard
Myogenic differentiation of mesenchymal stem cells in a newly developed neurotised AV-loop model. / Bitto, Franz F; Klumpp, Dorothee; Lange, Claudia; Boos, Anja M; Arkudas, Andreas; Bleiziffer, Oliver; Horch, Raymund E; Kneser, Ulrich; Beier, Justus P.
in: BIOMED RES INT, Jahrgang 2013, 01.01.2013, S. 935046.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Myogenic differentiation of mesenchymal stem cells in a newly developed neurotised AV-loop model
AU - Bitto, Franz F
AU - Klumpp, Dorothee
AU - Lange, Claudia
AU - Boos, Anja M
AU - Arkudas, Andreas
AU - Bleiziffer, Oliver
AU - Horch, Raymund E
AU - Kneser, Ulrich
AU - Beier, Justus P
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Generation of axially vascularized muscle tissue constitutes a promising new approach to restoration of damaged muscle tissue. Mesenchymal stemcells (MSC), with their ability to be expanded to large cell numbers without losing their differentiation capacity into the myogenic lineage, could offer a promising cell source to generate neomuscle tissue. In vitro experiments showed that cocultures of primary myoblasts and MSC undergo myogenic differentiation by stimulation with bFGF and dexamethasone. A newly developed AV-Loop model with neurotization was established in this study. It encompasses axial vascularization and the additional implantation of a motor nerve serving as myogenic stimulator. Myoblasts and MSCs were coimplantated in a prevascularized isolation chamber. Cells were differentiated by addition of bFGF and dexamethasone plus implantation of a motor nerve. After 8 weeks, we could observe areas of myogenic differentiation with α -sarcomeric actin and MHC expression in the constructs. Quantitative PCR analysis showed an expression of myogenic markers in all specimens. Thus, neurotization and addition of bFGF and dexamethasone allow myogenic differentiation of MSC in an axially vascularized in vivo model for the first time. These findings are a new step towards clinical applicability of skeletal muscle tissue engineering and display its potential for regenerative medicine.
AB - Generation of axially vascularized muscle tissue constitutes a promising new approach to restoration of damaged muscle tissue. Mesenchymal stemcells (MSC), with their ability to be expanded to large cell numbers without losing their differentiation capacity into the myogenic lineage, could offer a promising cell source to generate neomuscle tissue. In vitro experiments showed that cocultures of primary myoblasts and MSC undergo myogenic differentiation by stimulation with bFGF and dexamethasone. A newly developed AV-Loop model with neurotization was established in this study. It encompasses axial vascularization and the additional implantation of a motor nerve serving as myogenic stimulator. Myoblasts and MSCs were coimplantated in a prevascularized isolation chamber. Cells were differentiated by addition of bFGF and dexamethasone plus implantation of a motor nerve. After 8 weeks, we could observe areas of myogenic differentiation with α -sarcomeric actin and MHC expression in the constructs. Quantitative PCR analysis showed an expression of myogenic markers in all specimens. Thus, neurotization and addition of bFGF and dexamethasone allow myogenic differentiation of MSC in an axially vascularized in vivo model for the first time. These findings are a new step towards clinical applicability of skeletal muscle tissue engineering and display its potential for regenerative medicine.
KW - Animals
KW - Cell Differentiation
KW - Cell Lineage
KW - Coculture Techniques
KW - Dexamethasone
KW - Fibroblast Growth Factors
KW - Humans
KW - Mesenchymal Stromal Cells
KW - Muscle, Skeletal
KW - Myoblasts
KW - Rats
KW - Regenerative Medicine
KW - Tissue Engineering
U2 - 10.1155/2013/935046
DO - 10.1155/2013/935046
M3 - SCORING: Journal article
C2 - 24106724
VL - 2013
SP - 935046
JO - BIOMED RES INT
JF - BIOMED RES INT
SN - 2314-6133
ER -